A study to test how BI 764532 is taken up by tumours in people with small-cell lung cancer or neuroendocrine cancer

2022-501818-54-00 Protocol 1438-0004 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 22 Feb 2024 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol 1438-0004

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 12
Countries 1
Sites 1

Small cell lung carcinoma (SCLC)

Key facts

Sponsor
Boehringer Ingelheim International GmbH
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
22 Feb 2024 → ongoing
Decision date (initial)
2023-08-17
Transition trial
No
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
No

External identifiers

EU CT number
2022-501818-54-00
WHO UTN
U1111-1291-7129

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Small cell lung carcinoma (SCLC)

VersionLevelCodeTermSystem organ class
21.0 LLT 10048683 Advanced cancer 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Boehringer Ingelheim International GmbH

Sponsor organisation
Boehringer Ingelheim International GmbH
Address
Binger Strasse 173
City
Ingelheim Am Rhein
Postcode
55216
Country
Germany

Scientific contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Public contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ongoing, recruiting 12 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ongoing, recruiting
Amsterdam UMC
Afdeling Geneeskundige Oncologie, De Boelelaan 1117, 1081 HV, Amsterdam

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2024-02-22 2024-08-06

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-05-05 Netherlands Acceptable
2023-08-14
2023-08-17
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-01-16 Netherlands Acceptable
2023-08-14
2024-01-16
3 SUBSTANTIAL MODIFICATION SM-1 2024-09-18 Netherlands Acceptable
2024-12-05
2024-12-10
4 SUBSTANTIAL MODIFICATION SM-2 2025-12-04 Netherlands Acceptable
2026-02-03
2026-02-03
5 SUBSTANTIAL MODIFICATION SM-3 2026-03-26 Netherlands Acceptable
2026-05-12
2026-05-15